ORB-021 In Patients With Advanced Solid Tumors
Latest Information Update: 01 Oct 2024
At a glance
- Drugs ORB 021 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Orionis Biosciences
- 01 Oct 2024 New trial record
Latest Information Update: 01 Oct 2024